
    
      The Primary objective is to determine the best objective response rate (ORR) of ramucirumab
      when administered to participants with metastatic renal cell carcinoma (RCC) whose disease
      has progressed during therapy with a tyrosine kinase inhibitor (TKI, sunitinib and/or
      sorafenib) or who have developed intolerance to these agents.
    
  